Carlos Canelo-Aybar

Carlos Canelo-Aybar

Auto-generated profile, based on publicly available information

Carlos Canelo-Aybar

Institut de Recerca Sant Pau (IR Sant Pau) and Centro Cochrane Iberoamericano, Barcelona, Spain (C.C.-A.)

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CCCarlos Canelo-Aybar
Carlos Canelo-Aybar
MPMargarita Posso
Margarita Posso
NMNadia Montero
Nadia Montero
ISIvan Solà
Ivan Solà
ZSZuleika Saz-Parkinson
Zuleika Saz-Parkinson
PAPablo Alonso-Coello
Pablo Alonso-Coello
Background: Although mammography screening is recommended in most European countries, the balance between the benefits and harms of different screening intervals is still a matter of debate. This review informed the European Commission Initiative on Breast Cancer (BC) recommendations. Methods: We searched PubMed, EMBASE, and the Cochrane Library to identify RCTs, observational or modelling studies, comparing desirable (BC deaths averted, QALYs, BC stage, interval cancer) and undesirable (overdiagnosis, false positive related, radiation related) effects from annual, biennial, or triennial mammography screening in women of average risk for BC. We assessed the certainty of the evidence using the GRADE approach. Results: We included one RCT, 13 observational, and 11 modelling studies. In women 50–69, annual compared to biennial screening may have small additional benefits but an important increase in false positive results; triennial compared to biennial screening may have smaller benefits while avoiding some harms. In younger women (aged 45–49), annual compared to biennial screening had a smaller gain in benefits and larger harms, showing a less favourable balance in this age group than in women 50–69. In women 70–74, there were fewer additional harms and similar benefits with shorter screening intervals. The overall certainty of the evidence for each of these comparisons was very low. Conclusions: In women of average BC risk, screening intervals have different trade-offs for each age group. The balance probably favours biennial screening in women 50–69. In younger women, annual screening may have a less favourable balance, while in women aged 70–74 years longer screening intervals may be more favourable.

1 November 2017 in European Journal of Radiology
Verified
Journal Article
Closed access
MPMargarita Posso
Margarita Posso
Teresa PuigTeresa Puig
Teresa Puig
MCMisericòrdia Carles
Misericòrdia Carles
MRMontserrat Rue
Montserrat Rue
CCCarlos Canelo-Aybar
Carlos Canelo-Aybar
XBXavier Bonfill
Xavier Bonfill

15 November 2016 in Science and Engineering Ethics
Verified
Journal Article
Open access
PDF file
ACAndres M. Carnero
Andres M. Carnero
PMPercy Manuel Mayta-Tristán
Percy Manuel Mayta-Tristán
KKKelika A. Konda
Kelika A. Konda
EMEdward Mezones-Holguin
Edward Mezones-Holguin
ABAntonio Bernabe-Ortiz
Antonio Bernabe-Ortiz
ALAndres Lescano
Andres Lescano
Plagiarism is a serious, yet widespread type of research misconduct, and is often neglected in developing countries. Despite its far-reaching implications, plagiarism is poorly acknowledged and discussed in the academic setting, and insufficient evidence exists in Latin America and developing countries to inform the development of preventive strategies. In this context, we present a longitudinal case study of seven instances of plagiarism and cheating arising in four consecutive classes (2011–2014) of an Epidemiology Masters program in Lima, Peru, and describes the implementation and outcomes of a multifaceted, “zero-tolerance” policy aimed at introducing research integrity. Two cases involved cheating in graded assignments, and five cases correspond to plagiarism in the thesis protocol. Cases revealed poor awareness of high tolerance to plagiarism, poor academic performance, and widespread writing deficiencies, compensated with patchwriting and copy-pasting. Depending on the events’ severity, penalties included course failure (6/7) and separation from the program (3/7). Students at fault did not engage in further plagiarism. Between 2011 and 2013, the Masters program sequentially introduced a preventive policy consisting of: (i) intensified research integrity and scientific writing education, (ii) a stepwise, cumulative writing process; (iii) honor codes; (iv) active search for plagiarism in all academic products; and (v) a “zero-tolerance” policy in response to documented cases. No cases were detected in 2014. In conclusion, plagiarism seems to be widespread in resource-limited settings and a greater response with educational and zero-tolerance components is needed to prevent it.

6 May 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
EGEna Niño De Guzman
Ena Niño De Guzman
YSYang Song
Yang Song
PAPablo Alonso
Pablo Alonso
CCCarlos Canelo-Aybar
Carlos Canelo-Aybar
LNLuciana Neamtiu
Luciana Neamtiu
IRIgnacio Ricci-Cabello
Ignacio Ricci-Cabello
Purpose: Clinical guidelines’ (CGs) adherence supports high-quality care. However, healthcare providers do not always comply with CGs recommendations. This systematic literature review aims to assess the extent of healthcare providers’ adherence to breast cancer CGs in Europe and to identify the factors that impact on healthcare providers’ adherence. Methods: We searched for systematic reviews and quantitative or qualitative primary studies in MEDLINE and Embase up to May 2019. The eligibility assessment, data extraction, and risk of bias assessment were conducted by one author and cross-checked by a second author. We conducted a narrative synthesis attending to the modality of the healthcare process, methods to measure adherence, the scope of the CGs, and population characteristics. Results: Out of 8137 references, we included 41 primary studies conducted in eight European countries. Most followed a retrospective cohort design (19/41; 46%) and were at low or moderate risk of bias. Adherence for overall breast cancer care process (from diagnosis to follow-up) ranged from 54 to 69%; for overall treatment process [including surgery, chemotherapy (CT), endocrine therapy (ET), and radiotherapy (RT)] the median adherence was 57.5% (interquartile range (IQR) 38.8–67.3%), while for systemic therapy (CT and ET) it was 76% (IQR 68–77%). The median adherence for the processes assessed individually was higher, ranging from 74% (IQR 10–80%), for the follow-up, to 90% (IQR 87–92.5%) for ET. Internal factors that potentially impact on healthcare providers’ adherence were their perceptions, preferences, lack of knowledge, or intentional decisions. Conclusions: A substantial proportion of breast cancer patients are not receiving CGs-recommended care. Healthcare providers’ adherence to breast cancer CGs in Europe has room for improvement in almost all care processes. CGs development and implementation processes should address the main factors that influence healthcare providers' adherence, especially patient-related ones. Registration: PROSPERO (CRD42018092884).

13 December 2016 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
CCCarlos Canelo-Aybar
Carlos Canelo-Aybar
GBGraciela Balbin
Graciela Balbin
ÁPÁngela Perez-Gomez
Ángela Perez-Gomez
IFIvan Florez
Ivan Florez
Guías de práctica clínica en el Perú: evaluación de su calidad usando el instrumento AGREE II

CCCaterina Checa
Caterina Checa
CCCarlos Canelo-Aybar
Carlos Canelo-Aybar
SSStefanie Suclupe
Stefanie Suclupe
DGDavid Ginesta-López
David Ginesta-López
ABAnna Berenguera
Anna Berenguera
MPMargarita Posso
Margarita Posso
Aims: Nurse-led case management (CM) may improve quality of life (QoL) for advanced heart failure (HF) patients. No systematic review (SR), however, has summarized its effectiveness/cost-effectiveness. We aimed to evaluate the effect of such programs in primary care settings in advanced HF patients. We examined and summarized evidence on QoL, mortality, hospitalization, self-care, and cost-effectiveness. Methods and results: The MEDLINE, CINAHL, Embase, Clinical Trials, WHO, Registry of International Clinical Trials, and Central Cochrane were searched up to March 2022. The Consensus Health Economic Criteria instrument to assess risk-of-bias in economic evaluations, Cochrane risk-of-bias 2 for clinical trials, and an adaptation of Robins-I for quasi-experimental and cohort studies were employed. Results from nurse-led CM programs did not reduce mortality (RR 0.78, 95% CI 0.53 to 1.15; participants = 1345; studies = 6; I2 = 47%). They decreased HF hospitalizations (HR 0.79, 95% CI 0.68 to 0.91; participants = 1989; studies = 8; I2 = 0%) and all-cause ones (HR 0.73, 95% CI 0.60 to 0.89; participants = 1012; studies = 5; I2 = 36%). QoL improved in medium-term follow-up (SMD 0.18, 95% CI 0.05 to 0.32; participants = 1228; studies = 8; I2 = 28%), and self-care was not statistically significant improved (SMD 0.66, 95% CI −0.84 to 2.17; participants = 450; studies = 3; I2 = 97%). A wide variety of costs ranging from USD 4975 to EUR 27,538 was observed. The intervention was cost-effective at ≤EUR 60,000/QALY. Conclusions: Nurse-led CM reduces all-cause hospital admissions and HF hospitalizations but not all-cause mortality. QoL improved at medium-term follow-up. Such programs could be cost-effective in high-income countries.